Volume 7 Supplement 1

VI Madrid Breast Cancer Conference: Changes in the treatment of breast cancer

Open Access

Methods for gene expression profiling in clinical trials for breast cancer

  • S Paik1
Breast Cancer Research20057(Suppl 1):S3

https://doi.org/10.1186/bcr1207

Published: 27 May 2005

High throughput gene expression profiling provides a powerful tool for discovery of prognostic and predictive markers for breast cancer [14]. The main limitation to this approach is the requirement for high-quality RNA, which is difficult in the multicenter clinical trial setting. One solution is to use RNAlater, which allows procurement and shipping of tissue specimens at room temperature [5, 6]. The National Surgical Adjuvant Breast and Bowel Project (NSABP) has conducted a pilot study to procure pretreatement core biopsy specimens in a neoadjuvant study. Most of the samples in this study provided high-quality RNA, as determined by Bioanalyzer and Affymetrix GeneChip analyses. When combined with a RNA amplification method, quality data could be obtained from 10 ng of total RNA as starting material. NSABP currently has two neoadjuvant trials in which pretreatment specimens are procured in RNAlater. However, the typical practice pattern in the USA makes it difficult to procure tissue in the adjuvant setting even with the use of RNAlater. Therefore, methods that permit high throughput gene expression profiling of formalin-fixed, paraffin-embedded materials are in great need. Such methods will also allow interrogation of archived tissue banks with annotation established from previously finished trials and will therefore shorten the time for marker development and validation. Chemical modification by formalin and degradation during storage make RNA extracted from paraffin a poor substrate for gene expression profiling [7]. We have examined both microarray and RT-PCR platforms for this purpose. In general microarray analysis using the Arcturus Paradise system has been a disappointment in our hands, with high rate for assay failure for materials older than 3 years. However, there are RNA amplification and labeling methods in development that are not dependent on oligo-dT priming for cDNA synthesis and may provide better results. In collaboration with Genomic Health, Inc., we have explored the use of high-throughput real time RT-PCR for discovery and validation of prognostic markers for node negative and estrogen receptor positive breast cancer [8]. This has resulted in development of the OncotypeDx assay, which is offered as a commercial reference laboratory test. The disadvantage of real-time RT-PCR assays is relatively low throughput (less than 1000 genes, even at industrial scale). DASL assay from Illumina is a kind of hybrid between PCR and microarray platforms, and may provide relatively cost-efficient means by which to assay many candidate genes using degraded RNA obtainable from paraffin blocks [9].

Authors’ Affiliations

(1)
Division of Pathology, National Surgical Adjuvant Breast and Bowel Project

References

  1. Pusztai L, Ayers M, Stec J, et al: Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003, 9: 2406-2415.PubMedGoogle Scholar
  2. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.View ArticlePubMedPubMed CentralGoogle Scholar
  3. van 't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a.View ArticlePubMedGoogle Scholar
  4. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.View ArticleGoogle Scholar
  5. Grotzer MA, Patti R, Geoerger B, et al: Biological stability of RNA isolated from RNAlater-treated brain tumor and neuroblastoma xenografts. Med Pediatr Oncol. 2000, 34: 438-442. 10.1002/(SICI)1096-911X(200006)34:6<438::AID-MPO12>3.0.CO;2-Q.View ArticlePubMedGoogle Scholar
  6. Mutter GL, Zahrieh D, Liu C, et al: Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics. 2004, 5: 88-10.1186/1471-2164-5-88.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Masuda N, Ohnishi T, Kawamoto S, et al: Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res. 1999, 27: 4436-4443. 10.1093/nar/27.22.4436.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004, 351: 2817-2826. 10.1056/NEJMoa041588.View ArticlePubMedGoogle Scholar
  9. Bibikova M, Talantov D, Chudin E, et al: Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol. 2004, 165: 1799-1807.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© BioMed Central 2005

Advertisement